Gantenerumab
- Generic Name
- Gantenerumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1043556-46-2
- Unique Ingredient Identifier
- 4DF060P933
- Background
Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and c...
- Associated Conditions
- -
- Associated Therapies
- -
A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT02711423
- Locations
- 🇺🇸
Bioclinica Research, Orlando, Florida, United States
A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT02133937
A Study of Gantenerumab in Participants With Mild Alzheimer Disease
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 389
- Registration Number
- NCT02051608
- Locations
- 🇺🇸
Richmond Behavioral Associates, Staten Island, New York, United States
🇨🇦Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
🇺🇸Banner Sun Health Research Insitute, Sun City, Arizona, United States
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 490
- Registration Number
- NCT01760005
- Locations
- 🇨🇦
UBC Hospital, Vancouver, British Columbia, Canada
🇺🇸University of Washington, Seattle, Washington, United States
🇫🇷CHU de Rouen - Hôpital Charles Nicolle, Rouen, Seine Maritime, France
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT01656525
- Locations
- 🇯🇵
Kansai region, Kansai, Japan
🇯🇵Kanto region,, Kanto, Japan
🇯🇵Kyushu region, Kyushu, Japan
A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT01636531
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 799
- Registration Number
- NCT01224106
- Locations
- 🇺🇸
Butler Hospital, Providence, Rhode Island, United States
🇧🇷Hospital Mae de Deus, Porto Alegre, RS, Brazil
🇩🇰Rigshospitalet, Hukommelsesklinikken, Koebenhavn Oe, Denmark
A Multiple Ascending Dose Study of R1450 in Patients With Alzheimer Disease.
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT00531804
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.